rs137852665
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_002180.3(IGHMBP2):c.1540G>A(p.Glu514Lys) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000131 in 1,606,692 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_002180.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
IGHMBP2 | NM_002180.3 | c.1540G>A | p.Glu514Lys | missense_variant, splice_region_variant | 11/15 | ENST00000255078.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
IGHMBP2 | ENST00000255078.8 | c.1540G>A | p.Glu514Lys | missense_variant, splice_region_variant | 11/15 | 1 | NM_002180.3 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000131 AC: 2AN: 152212Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000252 AC: 6AN: 238380Hom.: 0 AF XY: 0.0000465 AC XY: 6AN XY: 128910
GnomAD4 exome AF: 0.0000131 AC: 19AN: 1454480Hom.: 0 Cov.: 30 AF XY: 0.00000968 AC XY: 7AN XY: 722918
GnomAD4 genome ? AF: 0.0000131 AC: 2AN: 152212Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74352
ClinVar
Submissions by phenotype
Autosomal recessive distal spinal muscular atrophy 1 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 17, 2023 | - - |
Pathogenic, criteria provided, single submitter | research | Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine | Aug 18, 2015 | This variant has been previously reported as disease-causing and was identified with another variant in this gene, in an individual with congenital hypotonia and respiratory involvement. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 12, 2023 | The c.1540G>A (p.E514K) alteration is located in exon 11 (coding exon 11) of the IGHMBP2 gene. This alteration results from a G to A substitution at nucleotide position 1540, causing the glutamic acid (E) at amino acid position 514 to be replaced by a lysine (K). Based on data from gnomAD, the A allele has an overall frequency of 0.003% (6/238380) total alleles studied. The highest observed frequency was 0.006% (6/107112) of European (non-Finnish) alleles. This alteration was detected in the homozygous state, and in conjunction with another alteration in IGHMBP2, in multiple individuals with IGHMBP2-related neuropathy (Waldrop, 2019; Stalpers, 2013; Grohmann, 2003; Megarbane, 2022; Felice, 2021; Gonzaga-Jauregui, 2015). This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Autosomal recessive distal spinal muscular atrophy 1;C4015349:Charcot-Marie-Tooth disease axonal type 2S Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 06, 2023 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 514 of the IGHMBP2 protein (p.Glu514Lys). This variant is present in population databases (rs137852665, gnomAD 0.006%). This missense change has been observed in individuals with spinal muscular atrophy with respiratory distress type 1 (SMARD1) (PMID: 11528396, 14681881, 15503272, 26257172). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 9112). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 23, 2015 | The E514K variant has been previously reported in the homozygous state in a patient with SMARD1 and in the heterozygous state in a SMARD1 patient whom also had a second IGHMBP2 mutation (Grohmann et al., 2001; Grohmann et al., 2003; Diers et al., 2005; Gonzaga-Jauregui et al., 2015). It was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project. The E514K variant is a non-conservative amino acid substitution, which occurs at a position that is conserved across species. Therefore, E514K is interpreted to be a pathogenic variant - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at